Mimedx (MDXG) Share-based Compensation Growth (1y) (2012 - 2026)
Mimedx (MDXG) Share-based Compensation Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,899.87 Bn | 1,899.81 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.43 Bn | 465.64 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 123.43 Bn | 116.19 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 70.20 Bn | 61.44 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 61.75 Bn | 61.75 Bn | - | - |
| 8 | Argenx Se | 56.15 Bn | 50.96 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | - |
| 10 | Mimedx | 639.06 Mn | 479.29 Mn | 41.62 Mn | -22.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.66% |
| Dec 31, 2025 | 70.00% |
| Sep 30, 2025 | -5,506.36% |
| Jun 30, 2025 | 456.50% |
| Mar 31, 2025 | -43.36% |
| Sep 30, 2024 | -97.49% |
| Jun 30, 2024 | -145.30% |
| Mar 31, 2024 | 11.17% |
| Sep 30, 2023 | 84.99% |
| Jun 30, 2023 | -8.31% |
| Mar 31, 2023 | -2.35% |
| Dec 31, 2022 | -94.36% |
| Sep 30, 2022 | -37.76% |
| Jun 30, 2022 | 8.32% |
| Mar 31, 2022 | 24.32% |
| Dec 31, 2021 | 12,640.00% |
| Sep 30, 2021 | 4,724.05% |
| Jun 30, 2021 | 501.18% |
| Mar 31, 2021 | -3.97% |
| Dec 31, 2020 | -139.27% |